MacroGenics | MGNX - Cash And Equivalent


MacroGenics reported $80.13M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Genmab DKK 1.3B 323M Jun/2025
Geron USD 79.44M 553K Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
MacroGenics USD 80.13M 50.56M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Xencor USD 54.07M 25.78M Dec/2025